{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:51:35Z","timestamp":1792165895106,"version":"4.4.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00204-025-04103-2","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T13:37:10Z","timestamp":1749649030000},"page":"3935-3962","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Deriving safe limits for N-nitroso-bisoprolol by error-corrected next-generation sequencing (ecNGS) and benchmark dose (BMD) analysis, integrated with QM modeling and CYP-docking analysis"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2497-5211","authenticated-orcid":false,"given":"Stephanie","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4799-1086","authenticated-orcid":false,"given":"J\u00f6rg","family":"Schlingemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-9942","authenticated-orcid":false,"given":"George","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1814-9535","authenticated-orcid":false,"given":"Christian","family":"Brenneis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3248-6247","authenticated-orcid":false,"given":"Brunhilde","family":"Guessregen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9727-0477","authenticated-orcid":false,"given":"Jakub","family":"Kostal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1908-5351","authenticated-orcid":false,"given":"Jessica","family":"Dieckhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"issue":"15","key":"4103_CR1","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1021\/jf703741a","volume":"56","author":"M Baum","year":"2008","unstructured":"Baum M, Loeppky RN, Thielen S, Eisenbrand G (2008) Genotoxicity of glycidamide in comparison to 3-N-nitroso-oxazolidin-2-one. J Agric Food Chem 56(15):5989\u20135993. https:\/\/doi.org\/10.1021\/jf703741a","journal-title":"J Agric Food Chem"},{"key":"4103_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105704","volume":"154","author":"J Bercu","year":"2024","unstructured":"Bercu J, Dirat O, Dobo K et al (2024) N-Nitrosamine drug substance related impurities (NDSRIs)\u2014A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 Da. Regul Toxicol Pharmacol 154:105704. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105704","journal-title":"Regul Toxicol Pharmacol"},{"key":"4103_CR3","doi-asserted-by":"publisher","first-page":"105835","DOI":"10.1016\/j.yrtph.2025.105835","volume":"161","author":"J Bercu","year":"2025","unstructured":"Bercu J, Trejo-Martin A, Chen C et al (2025) HESI GTTC ring trial: concordance between ames and rodent carcinogenicity outcomes for N-Nitrosamines (NAs) with rat and hamster metabolic conditions. Regulat Toxicol Pharmacol 161:105835. https:\/\/doi.org\/10.1016\/j.yrtph.2025.105835","journal-title":"Regulat Toxicol Pharmacol"},{"issue":"Suppl 1","key":"4103_CR4","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.yrtph.2016.05.028","volume":"79","author":"JP Bercu","year":"2016","unstructured":"Bercu JP, Morinello EJ, Sehner C, Shipp BK, Weideman PA (2016) Point of departure (PoD) selection for the derivation of acceptable daily exposures (ADEs) for active pharmaceutical ingredients (APIs). Regul Toxicol Pharmacol 79(Suppl 1):S48-56. https:\/\/doi.org\/10.1016\/j.yrtph.2016.05.028","journal-title":"Regul Toxicol Pharmacol"},{"key":"4103_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2023.503685","volume":"891","author":"JP Bercu","year":"2023","unstructured":"Bercu JP, Zhang S, Sobol Z, Escobar PA, Van P, Schuler M (2023) Comparison of the transgenic rodent mutation assay, error corrected next generation duplex sequencing, and the alkaline comet assay to detect dose-related mutations following exposure to N-nitrosodiethylamine. Mutat Res Genet Toxicol Environ Mutagen 891:503685. https:\/\/doi.org\/10.1016\/j.mrgentox.2023.503685","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"4103_CR6","unstructured":"Brenneis C (2024) MSC3053438A \u2013 4-week oral mutagenicity study in mice using Duplex-Sequencing. Merck Healthcare KGaA, Darmstadt"},{"issue":"11","key":"4103_CR7","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1124\/dmd.114.059717","volume":"42","author":"P Buchwald","year":"2014","unstructured":"Buchwald P (2014) Activity-limiting role of molecular size: size-dependency of maximum activity for P450 inhibition as revealed by qHTS data. Drug Metab Dispos 42(11):1785\u20131790. https:\/\/doi.org\/10.1124\/dmd.114.059717","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"4103_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/minf.201300132","volume":"33","author":"P Buchwald","year":"2014","unstructured":"Buchwald P, Yamashita F (2014) Bilinear model for the size-dependency of the CYP3A4 inhibitory activity of structurally diverse compounds. Mol Inf 33(1):8\u201314. https:\/\/doi.org\/10.1002\/minf.201300132","journal-title":"Mol Inf"},{"key":"4103_CR9","unstructured":"Canada H (2024) Guidance on nitrosamine impurities in medications\u2014Evaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products. Adopted 2024-05-31. In: Canada H (ed) H164-327\/2024E-1-PDF."},{"key":"4103_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.comtox.2021.100186","author":"KP Cross","year":"2021","unstructured":"Cross KP, Ponting DJ (2021) Developing structure-activity relationships for N-nitrosamine activity. Comput Toxicol. https:\/\/doi.org\/10.1016\/j.comtox.2021.100186","journal-title":"Comput Toxicol"},{"key":"4103_CR11","unstructured":"Dalgaard P R Development Core Team (2010): R: a language and environment for statistical computing. In: 2010"},{"issue":"1","key":"4103_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12860-019-0218-z","volume":"20","author":"D Devaurs","year":"2019","unstructured":"Devaurs D, Antunes DA, Hall-Swan S et al (2019) Using parallelized incremental meta-docking can solve the conformational sampling issue when docking large ligands to proteins. BMC Mol Cell Biol 20(1):42. https:\/\/doi.org\/10.1186\/s12860-019-0218-z","journal-title":"BMC Mol Cell Biol"},{"issue":"8","key":"4103_CR13","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00204-023-03527-y","volume":"97","author":"AE Dodge","year":"2023","unstructured":"Dodge AE, LeBlanc DPM, Zhou G et al (2023) Duplex sequencing provides detailed characterization of mutation frequencies and spectra in the bone marrow of MutaMouse males exposed to procarbazine hydrochloride. Arch Toxicol 97(8):2245\u20132259. https:\/\/doi.org\/10.1007\/s00204-023-03527-y","journal-title":"Arch Toxicol"},{"issue":"16","key":"4103_CR14","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1002\/1873-3468.13489","volume":"593","author":"P Durairaj","year":"2019","unstructured":"Durairaj P, Fan L, Machalz D, Wolber G, Bureik M (2019) Functional characterization and mechanistic modeling of the human cytochrome P450 enzyme CYP4A22. FEBS Lett 593(16):2214\u20132225. https:\/\/doi.org\/10.1002\/1873-3468.13489","journal-title":"FEBS Lett"},{"key":"4103_CR15","unstructured":"EMA (2023) Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products, Appendix 2: Carcinogenic Potency Categorisation Approach (CPCA) for N-nitrosamines EMA\/451665\/2023"},{"key":"4103_CR16","unstructured":"EMA (2024a) Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products, 19 July 2024 EMA\/409815\/2020 Rev21"},{"key":"4103_CR17","unstructured":"EMA (2024b) Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products, Appendix 1: Acceptable intakes (AIs) established for N-nitrosamines EMA\/307633\/2024 \/Rev 8"},{"key":"4103_CR18","unstructured":"EMA (2024c) Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products, Appendix 3: Enhanced Ames Test Conditions for N-nitrosamines EMA\/120337\/2024"},{"key":"4103_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054684","author":"J Fahrer","year":"2023","unstructured":"Fahrer J, Christmann M (2023) DNA alkylation damage by nitrosamines and relevant DNA repair pathways. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24054684","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4103_CR20","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/carcin\/bgv114","volume":"36","author":"J Fahrer","year":"2015","unstructured":"Fahrer J, Frisch J, Nagel G et al (2015) DNA repair by MGMT, but not AAG, causes a threshold in alkylation-induced colorectal carcinogenesis. Carcinogenesis 36(10):1235\u20131244. https:\/\/doi.org\/10.1093\/carcin\/bgv114","journal-title":"Carcinogenesis"},{"key":"4103_CR21","unstructured":"FDA (2005) Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Guidance for Industry, July 2005"},{"key":"4103_CR22","unstructured":"FDA (2023) Recommended acceptable intake limits for nitrosamine drug substance-related impurities (NDSRIs)\u2014guidance for industry, August 2023"},{"key":"4103_CR23","unstructured":"FDA (2024) Control of nitrosamine impurities in human drugs\u2014guidance for industry, Revision 2, September 2024"},{"issue":"1\u20132","key":"4103_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0027-5107(90)90161-v","volume":"233","author":"JB Guttenplan","year":"1990","unstructured":"Guttenplan JB (1990) Mutagenesis by N-nitroso compounds: relationships to DNA adducts, DNA repair, and mutational efficiencies. Mutat Res 233(1\u20132):177\u2013187. https:\/\/doi.org\/10.1016\/0027-5107(90)90161-v","journal-title":"Mutat Res"},{"issue":"8","key":"4103_CR25","doi-asserted-by":"publisher","DOI":"10.2903\/j.efsa.2017.4971","volume":"15","author":"A Hardy","year":"2017","unstructured":"Hardy A, Benford D, Halldorsson T et al (2017) Guidance on the use of the weight of evidence approach in scientific assessments. EFSA J 15(8):e04971. https:\/\/doi.org\/10.2903\/j.efsa.2017.4971","journal-title":"EFSA J"},{"key":"4103_CR26","unstructured":"ICH (2023) ICH harmonized guideline: assessment and control of DNA-reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, M7(R2), Final version, adopted on 3 April 2023"},{"key":"4103_CR27","unstructured":"ICH (2024) ICH Harmonized Guideline: Impurities: Guideline for Residual Solvents Q3C(R9), Current Step 4 version, dated 24 January 2024"},{"issue":"6","key":"4103_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/mutage\/gei054","volume":"20","author":"GJ Jenkins","year":"2005","unstructured":"Jenkins GJ, Doak SH, Johnson GE, Quick E, Waters EM, Parry JM (2005) Do dose response thresholds exist for genotoxic alkylating agents? Mutagenesis 20(6):389\u2013398. https:\/\/doi.org\/10.1093\/mutage\/gei054","journal-title":"Mutagenesis"},{"key":"4103_CR29","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.toxlet.2024.07.061","volume":"399","author":"GE Johnson","year":"2024","unstructured":"Johnson GE (2024) S06\u201302 Consideration of dose-response in the assessment of genotoxic carcinogens. Toxicol Lett 399:S20. https:\/\/doi.org\/10.1016\/j.toxlet.2024.07.061","journal-title":"Toxicol Lett"},{"key":"4103_CR30","unstructured":"Johnson GE (2025) N-nitrosobisoprolol (NBP): Benchmark Dose Analysis of an error-corrected Next Generation Sequencing based repeat-dose gene mutation assay in vivo. Version 2; on behalf of Merck Healthcare KGaA"},{"issue":"5","key":"4103_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/em.22446","volume":"62","author":"GE Johnson","year":"2021","unstructured":"Johnson GE, Dobo K, Gollapudi B et al (2021) Permitted daily exposure limits for noteworthy N-nitrosamines. Environ Mol Mutagen 62(5):293\u2013305. https:\/\/doi.org\/10.1002\/em.22446","journal-title":"Environ Mol Mutagen"},{"key":"4103_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105672","volume":"152","author":"RA Jolly","year":"2024","unstructured":"Jolly RA, Cornwell PD, Noteboom J, Sayyed FB, Thapa B, Buckley LA (2024) Estimation of acceptable daily intake values based on modeling and in vivo mutagenicity of NDSRIs of fluoxetine, duloxetine and atomoxetine. Regul Toxicol Pharmacol 152:105672. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105672","journal-title":"Regul Toxicol Pharmacol"},{"key":"4103_CR33","unstructured":"Jolly RA, Trejo-Martin A, Bercu J, et al. (2025) Ames concordance with the in vivo TGR mutation assay for NDSRIs and relative in vivo TGR potency with exemplar nitrosamines. Regul Toxicol Pharmacol, in preparation"},{"issue":"12","key":"4103_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/ani7120088","volume":"7","author":"S Kappel","year":"2017","unstructured":"Kappel S, Hawkins P, Mendl MT (2017) To group or not to group? Good practice for housing male laboratory mice. Animals 7(12):88","journal-title":"Animals"},{"issue":"7364","key":"4103_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nature10413","volume":"477","author":"TM Keane","year":"2011","unstructured":"Keane TM, Goodstadt L, Danecek P et al (2011) Mouse genomic variation and its effect on phenotypes and gene regulation. Nature 477(7364):289\u2013294. https:\/\/doi.org\/10.1038\/nature10413","journal-title":"Nature"},{"key":"4103_CR36","doi-asserted-by":"crossref","unstructured":"Kostal J (2018) Quantum mechanics approaches in computational toxicology computational toxicology. pp 31\u201368","DOI":"10.1002\/9781119282594.ch2"},{"key":"4103_CR37","unstructured":"Kostal J The HESI QSAR-QM Project: bridging QM methods and the CPCA to enhance hazard assessment of N-nitrosamines In Silico. In: Updates on approaches to acceptable intakes of nitrosamine drug substance related impurities (NDSRIs) and Bioequivalence Assessment for Reformulated Drug Products, Center for Research on Complex Generics, Shady Grove, MD, USA, 2024"},{"issue":"2","key":"4103_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1021\/acs.chemrestox.2c00380","volume":"36","author":"J Kostal","year":"2023","unstructured":"Kostal J, Voutchkova-Kostal A (2023) Quantum-mechanical approach to predicting the carcinogenic potency of N-Nitroso impurities in pharmaceuticals. Chem Res Toxicol 36(2):291\u2013304. https:\/\/doi.org\/10.1021\/acs.chemrestox.2c00380","journal-title":"Chem Res Toxicol"},{"key":"4103_CR39","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.4c00482","author":"J Kostal","year":"2025","unstructured":"Kostal J, Voutchkova-Kostal A (2025) Tale of three N-nitrosamines and the variables needed to assess their carcinogenicity in silico incorporated into a single workflow. Chem Res Toxicol. https:\/\/doi.org\/10.1021\/acs.chemrestox.4c00482","journal-title":"Chem Res Toxicol"},{"key":"4103_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105640","volume":"150","author":"NL Kruhlak","year":"2024","unstructured":"Kruhlak NL, Schmidt M, Froetschl R et al (2024) Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: development and application of the Carcinogenic Potency Categorization Approach (CPCA). Regul Toxicol Pharmacol 150:105640. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105640","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"4103_CR41","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2019.03.001","volume":"177","author":"JE Kucab","year":"2019","unstructured":"Kucab JE, Zou X, Morganella S et al (2019) A Compendium of mutational signatures of environmental agents. Cell 177(4):821\u2013836. https:\/\/doi.org\/10.1016\/j.cell.2019.03.001","journal-title":"Cell"},{"issue":"4","key":"4103_CR42","first-page":"1044","volume":"37","author":"T Kuroki","year":"1977","unstructured":"Kuroki T, Drevon C, Montesano R (1977) Microsome-mediated mutagenesis in V79 Chinese hamster cells by various nitrosamines. Cancer Res 37(4):1044\u20131050","journal-title":"Cancer Res"},{"key":"4103_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111381","author":"T Kuvek","year":"2024","unstructured":"Kuvek T, Marcher C, Berteotti A, Lopez Carrillo V, Schleifer KJ, Oostenbrink C (2024) A computational pipeline observes the flexibility and dynamics of plant cytochrome P450 binding sites. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms252111381","journal-title":"Int J Mol Sci"},{"issue":"11","key":"4103_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw227","volume":"44","author":"Z Lai","year":"2016","unstructured":"Lai Z, Markovets A, Ahdesmaki M et al (2016) VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res 44(11):e108. https:\/\/doi.org\/10.1093\/nar\/gkw227","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"4103_CR45","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/s12864-022-08752-w","volume":"23","author":"DPM LeBlanc","year":"2022","unstructured":"LeBlanc DPM, Meier M, Lo FY et al (2022) Duplex sequencing identifies genomic features that determine susceptibility to benzo(a)pyrene-induced in vivo mutations. BMC Genomics 23(1):542. https:\/\/doi.org\/10.1186\/s12864-022-08752-w","journal-title":"BMC Genomics"},{"key":"4103_CR103","unstructured":"Lhasa Limited (2022) Vitic complex nitrosamines - Understanding the mutagenic potential of structurally-complex (API-like) nitrosamines. https:\/\/www.lhasalimited.org\/Initiatives\/complex-nitrosamines.htm"},{"key":"4103_CR101","unstructured":"Lhasa Limited (2024) Lhasa Carcinogenicity Database. https:\/\/www.lhasalimited.org\/products\/lhasa-carcinogenicitydatabase.htm"},{"key":"4103_CR46","unstructured":"Lhasa Limited (2025) Vitic Complex Nitrosamines Database"},{"issue":"2","key":"4103_CR47","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00214-003-0518-3","volume":"111","author":"BJ Lynch","year":"2004","unstructured":"Lynch BJ, Truhlar DG (2004) Small basis sets for calculations of barrier heights, energies of reaction, electron affinities, geometries, and dipole moments. Theoret Chem Acc 111(2):335\u2013344. https:\/\/doi.org\/10.1007\/s00214-003-0518-3","journal-title":"Theoret Chem Acc"},{"issue":"3","key":"4103_CR48","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/d41573-023-00014-y","volume":"22","author":"F Marchetti","year":"2023","unstructured":"Marchetti F, Cardoso R, Chen CL et al (2023a) Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing. Nat Rev Drug Discov 22(3):165\u2013166. https:\/\/doi.org\/10.1038\/d41573-023-00014-y","journal-title":"Nat Rev Drug Discov"},{"key":"4103_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2023.108466","volume":"792","author":"F Marchetti","year":"2023","unstructured":"Marchetti F, Cardoso R, Chen CL et al (2023b) Error-corrected next generation sequencing\u2014promises and challenges for genotoxicity and cancer risk assessment. Mutat Res Rev Mutat Res 792:108466. https:\/\/doi.org\/10.1016\/j.mrrev.2023.108466","journal-title":"Mutat Res Rev Mutat Res"},{"issue":"3","key":"4103_CR102","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00357-014-9161-z","volume":"31","author":"F Murtagh","year":"2014","unstructured":"Murtagh F, Legendre P (2014) Ward\u2019s hierarchical agglomerative clustering method: which algorithms implement ward\u2019s criterion?. J Classif 31(3):274\u2013295. https:\/\/doi.org\/10.1007\/s00357-014-9161-z","journal-title":"J Classif"},{"issue":"1","key":"4103_CR50","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1021\/acs.jcim.9b00778","volume":"60","author":"NT Nguyen","year":"2020","unstructured":"Nguyen NT, Nguyen TH, Pham TNH et al (2020) Autodock Vina adopts more accurate binding poses but autodock4 forms better binding affinity. J Chem Inf Model 60(1):204\u2013211. https:\/\/doi.org\/10.1021\/acs.jcim.9b00778","journal-title":"J Chem Inf Model"},{"issue":"10","key":"4103_CR51","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1021\/acs.oprd.3c00100","volume":"27","author":"R Nudelman","year":"2023","unstructured":"Nudelman R, Kocks G, Mouton B et al (2023) The nitrosamine \u201cSaga\u201d: lessons learned from five years of scrutiny. Org Process Res Dev 27(10):1719\u20131735","journal-title":"Org Process Res Dev"},{"key":"4103_CR52","unstructured":"OECD (2020) OECD Guideline for the Testing of Chemicals, OECD TG 471, Bacterial Reverse Mutation Test, Corrected: 26 June 2020"},{"key":"4103_CR53","unstructured":"OECD (2022) OECD Guideline for the Testing of Chemicals, OECD TG 488, Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays. Adopted: 30 June 2022"},{"key":"4103_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105762","volume":"156","author":"DJ Ponting","year":"2024","unstructured":"Ponting DJ, Czich A, Felter SP et al (2024) Control of N-nitrosamine impurities in drug products: progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakes. Regul Toxicol Pharmacol 156:105762. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105762","journal-title":"Regul Toxicol Pharmacol"},{"key":"4103_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105681","volume":"152","author":"MW Powley","year":"2024","unstructured":"Powley MW, Sobol Z, Johnson GE et al (2024) N-nitrosamine impurity risk assessment in pharmaceuticals: utilizing In vivo mutation relative potency comparison to establish an acceptable intake for NTTP. Regul Toxicol Pharmacol 152:105681. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105681","journal-title":"Regul Toxicol Pharmacol"},{"key":"4103_CR56","doi-asserted-by":"crossref","unstructured":"Roper JM, Griffin TR, Johnson GE, Kostal J, Nudelman R (2025) Using N-nitrosodiethanolamine (NDELA) and N-nitrosopiperidine (NPIP) transgenic rodent gene mutation data and quantum mechanical modeling to derive potency-based acceptable intakes for NDSRIs lacking robust carcinogenicity data. Environ Mol Mutagen in press","DOI":"10.1002\/em.70012"},{"issue":"1","key":"4103_CR57","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/em.22342","volume":"61","author":"JJ Salk","year":"2020","unstructured":"Salk JJ, Kennedy SR (2020) Next-generation genotoxicology: using modern sequencing technologies to assess somatic mutagenesis and cancer risk. Environ Mol Mutagen 61(1):135\u2013151. https:\/\/doi.org\/10.1002\/em.22342","journal-title":"Environ Mol Mutagen"},{"issue":"2","key":"4103_CR58","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1021\/acs.chemrestox.4c00476","volume":"38","author":"S Schieferdecker","year":"2025","unstructured":"Schieferdecker S, Vock E (2025) Quantum chemical evaluation and QSAR modeling of N-nitrosamine carcinogenicity. Chem Res Toxicol 38(2):325\u2013339. https:\/\/doi.org\/10.1021\/acs.chemrestox.4c00476","journal-title":"Chem Res Toxicol"},{"issue":"5","key":"4103_CR59","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.xphs.2022.11.013","volume":"112","author":"J Schlingemann","year":"2023","unstructured":"Schlingemann J, Burns MJ, Ponting DJ et al (2023) The landscape of potential small and drug substance related nitrosamines in pharmaceuticals. J Pharm Sci 112(5):1287\u20131304. https:\/\/doi.org\/10.1016\/j.xphs.2022.11.013","journal-title":"J Pharm Sci"},{"issue":"49","key":"4103_CR60","doi-asserted-by":"publisher","first-page":"21450","DOI":"10.1021\/acs.est.4c07236","volume":"58","author":"DM Schuster","year":"2024","unstructured":"Schuster DM, LeBlanc DPM, Zhou G et al (2024) Dose-related mutagenic and clastogenic effects of benzo[b]fluoranthene in mouse somatic tissues detected by duplex sequencing and the micronucleus assay. Environ Sci Technol 58(49):21450\u201321463. https:\/\/doi.org\/10.1021\/acs.est.4c07236","journal-title":"Environ Sci Technol"},{"key":"4103_CR61","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41021-017-0076-x","volume":"39","author":"K Shiizaki","year":"2017","unstructured":"Shiizaki K, Kawanishi M, Yagi T (2017) Modulation of benzo[a]pyrene-DNA adduct formation by CYP1 inducer and inhibitor. Genes Environ 39:14. https:\/\/doi.org\/10.1186\/s41021-017-0076-x","journal-title":"Genes Environ"},{"key":"4103_CR62","doi-asserted-by":"crossref","unstructured":"Smith-Roe SL, Hobbs CA, Hull V et al (2023a) Adopting duplex sequencing technology for genetic toxicity testing: a proof-of-concept mutagenesis experiment with N-Ethyl-N-Nitrosourea (ENU)-exposed rats bioRxiv. 20230509 edn","DOI":"10.1101\/2023.05.08.539833"},{"key":"4103_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2023.503669","volume":"891","author":"SL Smith-Roe","year":"2023","unstructured":"Smith-Roe SL, Hobbs CA, Hull V et al (2023b) Adopting duplex sequencing technology for genetic toxicity testing: a proof-of-concept mutagenesis experiment with N-ethyl-N-nitrosourea (ENU)-exposed rats. Mutat Res Genet Toxicol Environ Mutagen 891:503669. https:\/\/doi.org\/10.1016\/j.mrgentox.2023.503669","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"issue":"2","key":"4103_CR64","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1021\/acs.jcim.8b00545","volume":"59","author":"M Su","year":"2019","unstructured":"Su M, Yang Q, Du Y et al (2019) Comparative assessment of scoring functions: the CASF-2016 update. J Chem Inf Model 59(2):895\u2013913. https:\/\/doi.org\/10.1021\/acs.jcim.8b00545","journal-title":"J Chem Inf Model"},{"issue":"4\u20135","key":"4103_CR65","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/mnfr.200500227","volume":"50","author":"S Thielen","year":"2006","unstructured":"Thielen S, Baum M, Hoffmann M, Loeppky RN, Eisenbrand G (2006) Genotoxicity of glycidamide in comparison to (+\/-)-anti-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide and alpha-acetoxy-N-nitroso-diethanolamine in human blood and in mammalian V79-cells. Mol Nutr Food Res 50(4\u20135):430\u2013436. https:\/\/doi.org\/10.1002\/mnfr.200500227","journal-title":"Mol Nutr Food Res"},{"issue":"5","key":"4103_CR66","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1039\/b919471a","volume":"12","author":"M Torrent-Sucarrat","year":"2010","unstructured":"Torrent-Sucarrat M, De Proft F, Ayers PW, Geerlings P (2010) On the applicability of local softness and hardness. Phys Chem Chem Phys 12(5):1072\u20131080. https:\/\/doi.org\/10.1039\/b919471a","journal-title":"Phys Chem Chem Phys"},{"issue":"52","key":"4103_CR67","doi-asserted-by":"publisher","first-page":"33414","DOI":"10.1073\/pnas.2013724117","volume":"117","author":"CC Valentine 3rd","year":"2020","unstructured":"Valentine CC 3rd, Young RR, Fielden MR et al (2020) Direct quantification of in vivo mutagenesis and carcinogenesis using duplex sequencing. Proc Natl Acad Sci U S A 117(52):33414\u201333425. https:\/\/doi.org\/10.1073\/pnas.2013724117","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"4103_CR68","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1021\/acs.chemrestox.2c00224","volume":"35","author":"A Voutchkova-Kostal","year":"2022","unstructured":"Voutchkova-Kostal A, Vaccaro S, Kostal J (2022) Computer-aided discovery and redesign for respiratory sensitization: a tiered mechanistic model to deliver robust performance across a diverse chemical space. Chem Res Toxicol 35(11):2097\u20132106. https:\/\/doi.org\/10.1021\/acs.chemrestox.2c00224","journal-title":"Chem Res Toxicol"},{"key":"4103_CR69","unstructured":"WHO (2023) Web Annex A. World Health Organization Model List of Essential Medicines\u201423rd List, 2023. In: The selection and use of essential medicines 2023: Executive summary of the report of the 24th WHO Expert Committee on the Selection and Use of Essential Medicines, 24\u201328 April 2023. Geneva: World Health Organization; 2023 (WHO\/MHP\/HPS\/EML\/2023.02). Licence: CC BYNC-SA 3.0 IGO"},{"issue":"9","key":"4103_CR70","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/em.22137","volume":"58","author":"JW Wills","year":"2017","unstructured":"Wills JW, Johnson GE, Battaion HL, Slob W, White PA (2017) Comparing BMD-derived genotoxic potency estimations across variants of the transgenic rodent gene mutation assay. Environ Mol Mutagen 58(9):632\u2013643. https:\/\/doi.org\/10.1002\/em.22137","journal-title":"Environ Mol Mutagen"},{"issue":"3","key":"4103_CR71","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/mutage\/gev085","volume":"31","author":"JW Wills","year":"2016","unstructured":"Wills JW, Johnson GE, Doak SH, Soeteman-Hernandez LG, Slob W, White PA (2016a) Empirical analysis of BMD metrics in genetic toxicology part I: in vitro analyses to provide robust potency rankings and support MOA determinations. Mutagenesis 31(3):255\u2013263. https:\/\/doi.org\/10.1093\/mutage\/gev085","journal-title":"Mutagenesis"},{"issue":"3","key":"4103_CR72","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/mutage\/gew009","volume":"31","author":"JW Wills","year":"2016","unstructured":"Wills JW, Long AS, Johnson GE et al (2016b) Empirical analysis of BMD metrics in genetic toxicology part II: in vivo potency comparisons to promote reductions in the use of experimental animals for genetic toxicity assessment. Mutagenesis 31(3):265\u2013275. https:\/\/doi.org\/10.1093\/mutage\/gew009","journal-title":"Mutagenesis"},{"issue":"10","key":"4103_CR73","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1021\/jz100247x","volume":"1","author":"D Wondrousch","year":"2010","unstructured":"Wondrousch D, B\u00f6hme A, Thaens D, Ost N, Sch\u00fc\u00fcrmann G (2010) Local electrophilicity predicts the toxicity-relevant reactivity of Michael acceptors. J Phys Chem Lett 1(10):1605\u20131610. https:\/\/doi.org\/10.1021\/jz100247x","journal-title":"J Phys Chem Lett"},{"issue":"3","key":"4103_CR74","doi-asserted-by":"publisher","first-page":"R46","DOI":"10.1186\/gb-2014-15-3-r46","volume":"15","author":"DE Wood","year":"2014","unstructured":"Wood DE, Salzberg SL (2014) Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol 15(3):R46. https:\/\/doi.org\/10.1186\/gb-2014-15-3-r46","journal-title":"Genome Biol"},{"issue":"12","key":"4103_CR75","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1007\/s00204-017-2037-3","volume":"91","author":"A Zeller","year":"2017","unstructured":"Zeller A, Duran-Pacheco G, Guerard M (2017) An appraisal of critical effect sizes for the benchmark dose approach to assess dose-response relationships in genetic toxicology. Arch Toxicol 91(12):3799\u20133807. https:\/\/doi.org\/10.1007\/s00204-017-2037-3","journal-title":"Arch Toxicol"},{"issue":"2","key":"4103_CR76","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/mutage\/gey005","volume":"33","author":"A Zeller","year":"2018","unstructured":"Zeller A, Pfuhler S, Albertini S et al (2018) A critical appraisal of the sensitivity of in vivo genotoxicity assays in detecting human carcinogens. Mutagenesis 33(2):179\u2013193. https:\/\/doi.org\/10.1093\/mutage\/gey005","journal-title":"Mutagenesis"},{"issue":"3","key":"4103_CR77","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/em.70007","volume":"66","author":"S Zhang","year":"2025","unstructured":"Zhang S, Cheung J, Kostal J, Voutchkova-Kostal A, Schuler M (2025) Re-evaluating acceptable intake: a comparative study of N-Nitrosomorpholine and N-Nitroso reboxetine potency. Environ Mol Mutagen 66(3):80\u201398. https:\/\/doi.org\/10.1002\/em.70007","journal-title":"Environ Mol Mutagen"},{"key":"4103_CR78","doi-asserted-by":"crossref","unstructured":"Zhang S, Coffing SL, Gunther WC et al (2024) Assessing the genotoxicity of N-nitrosodiethylamine with three in vivo endpoints in male Big Blue(R) transgenic and wild-type C57BL\/6N mice Environ Mol Mutagen. 20240716","DOI":"10.1002\/em.22615"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-025-04103-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-025-04103-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-025-04103-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:31:39Z","timestamp":1758540699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-025-04103-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":81,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["4103"],"URL":"https:\/\/doi.org\/10.1007\/s00204-025-04103-2","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest, financial or otherwise. GJ is a consultant who evaluates the risks posed by pharmaceutical impurities. His clients did not influence the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}